Physician profile
Michael M Slaughter
NPI 1306151022
$979.56
in general payments reported to CMS, 2019-2025
14 companies · $182 in 2025
The $182 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $207 · 2023: $148 · 2024: $236 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $566.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cordis US Corp. | $208.11 | 2021-2024 | Outback, Mynxgrip, Aquatrack |
| Cardiovascular Systems INC. | $176.49 | 2021-2022 | |
| Abbott Laboratories | $128.66 | 2021-2024 | Diamondback Peripheral, Esprit |
| Tactile Systems Technology INC | $98.98 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Bolton Medical INC | $86.66 | 2025 | Treo Abdominal Stent-Graft System |
| Medtronic, INC. | $85.18 | 2024 | Ellipsys Vascular Access System, Endurant Iis |
| Mimedx Group, INC. | $42.71 | 2025 | |
| Janssen Pharmaceuticals, INC | $39.29 | 2021-2023 | Xarelto |
| Kerecis Limited | $22.75 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Cvrx, INC. | $19.61 | 2022 | |
| Ossur Americas, INC. | $19.27 | 2025 | |
| Neuros Medical, INC. | $17.94 | 2025 | Altius |
| Resmed Corp | $17.59 | 2022 | |
| Angiodynamics, INC. | $16.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Slaughter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.